Stoke Therapeutics (STOK) EBIT (2018 - 2026)
Stoke Therapeutics' (STOK) quarterly EBIT came in at -$53.4 million in Q1 2026, down 148.02% year-on-year from $111.2 million in Q1 2025, and up 13.06% quarter-over-quarter from -$61.4 million in Q4 2025.
Stoke Therapeutics (STOK) EBIT (2018 - 2026) Analysis & Trends
Stoke Therapeutics' EBIT history runs 9 years deep, the most recent figure standing at -$53.4 million for Q1 2026.
- On a quarterly basis, EBIT fell 148.02% year-over-year to -$53.4 million in Q1 2026; TTM through Mar 2026 was -$185.2 million, a 584.41% decrease from a year earlier, with the FY2025 full-year figure at -$20.6 million, up 79.69% from the prior year.
- EBIT grew to -$53.4 million in Q1 2026 per STOK's latest filing, from -$61.4 million in the prior quarter.
- Across five years, EBIT topped out at $111.2 million in Q1 2025 and bottomed at -$61.4 million in Q4 2025.
- The 5-year median for EBIT is -$27.3 million (2025), against an average of -$23.2 million.
- Biggest YoY gain for EBIT was 492.08% in 2025; the steepest drop was 350.0% in 2025.
- Year by year, EBIT stood at -$27.2 million in 2022, then dropped by 8.87% to -$29.6 million in 2023, then jumped by 53.85% to -$13.7 million in 2024, then slumped by 350.0% to -$61.4 million in 2025, then grew by 13.06% to -$53.4 million in 2026.
- Per Business Quant, the three latest STOK EBIT figures stand at -$53.4 million (Q1 2026), -$61.4 million (Q4 2025), and -$43.1 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -53.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.42 Mn |
| Dec 31, 2025 | -61.44 Mn |
| Sep 30, 2025 | -43.09 Mn |
| Jun 30, 2025 | -27.30 Mn |
| Mar 31, 2025 | 111.24 Mn |
| Dec 31, 2024 | -13.65 Mn |
| Sep 30, 2024 | -30.00 Mn |
| Jun 30, 2024 | -29.34 Mn |
| Mar 31, 2024 | -28.37 Mn |
| Dec 31, 2023 | -29.59 Mn |
| Sep 30, 2023 | -27.23 Mn |
| Jun 30, 2023 | -33.26 Mn |
| Mar 31, 2023 | -24.69 Mn |
| Dec 31, 2022 | -27.18 Mn |
| Sep 30, 2022 | -27.15 Mn |
| Jun 30, 2022 | -25.24 Mn |
| Mar 31, 2022 | -24.80 Mn |
| Dec 31, 2021 | -24.53 Mn |
| Sep 30, 2021 | -22.68 Mn |
| Jun 30, 2021 | -22.03 Mn |